Literature DB >> 17308959

Clinical presentation and response to therapy in patients with massive prolactin hypersecretion.

Susana Mascarell1, David H Sarne.   

Abstract

Prolactin hypersecretion from a pituitary adenoma usually results in a serum prolactin level less than 1,000 ng/ml. During therapy with a dopamine agonist, prolactin levels usually normalize and the tumors shrink substantially. In the past few years, we have seen three men who presented with serum prolactin levels greater than 10,000 ng/ml. All presented with large tumors, visual field deficits, and hypogonadotropic hypogonadism. All other pituitary hormones were normal. In all three patients, significant tumor shrinkage was achieved with improvement or resolution of headaches and visual field deficits. None of our patients has been able to achieve a normal prolactin or testosterone. A literature review identified 32 patients with prolactin levels of more than 10,000 ng/ml. Twenty-six (81%) were males. Most had large tumors, headaches and visual field defects. Even with the addition of surgery and/or radiation therapy to medical therapy, normalization of serum prolactin occurred in only six patients (19%) and only one man achieved a normal testosterone. We conclude that in patients with massive prolactin hypersecretion, therapy with a dopamine agonist will lead to tumor shrinkage and improvement of mass effects, but usually does not normalize prolactin or testosterone. Rather than waiting for maximal prolactin reduction, we would recommend early institution of testosterone replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17308959     DOI: 10.1007/s11102-007-0009-y

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  27 in total

1.  Giant prolactinoma and hook effect.

Authors:  P Pakzaban
Journal:  Neurology       Date:  2000-11-14       Impact factor: 9.910

2.  Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.

Authors:  Arijit Chattopadhyay; Anil Bhansali; Shariq R Masoodi
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  Giant basal prolactinoma extending into the nasal cavity.

Authors:  Y Iwai; A Hakuba; V K Khosla; M Nishikawa; J Katsuyama; Y Inoue; S Nishimura
Journal:  Surg Neurol       Date:  1992-04

4.  Neurological picture. A "giant" prolactinoma.

Authors:  U Reuter; S Mehraein; G Arnold; R Lehmann
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-09       Impact factor: 10.154

5.  High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas.

Authors:  E St-Jean; F Blain; R Comtois
Journal:  Clin Endocrinol (Oxf)       Date:  1996-03       Impact factor: 3.478

Review 6.  The pathology of pituitary tumors.

Authors:  S L Asa
Journal:  Endocrinol Metab Clin North Am       Date:  1999-03       Impact factor: 4.741

7.  Pergolide as primary therapy for macroprolactinomas.

Authors:  J J Orrego; W F Chandler; A L Barkan
Journal:  Pituitary       Date:  2000-12       Impact factor: 4.107

8.  Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen.

Authors:  J C Prior; T A Cox; D Fairholm; E Kostashuk; R Nugent
Journal:  J Clin Endocrinol Metab       Date:  1987-02       Impact factor: 5.958

9.  Dopamine agonists and pituitary tumor shrinkage.

Authors:  J S Bevan; J Webster; C W Burke; M F Scanlon
Journal:  Endocr Rev       Date:  1992-05       Impact factor: 19.871

10.  The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.

Authors:  Mary P Gillam; Stewart Middler; Daniel J Freed; Mark E Molitch
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

View more
  1 in total

1.  An unusual association of neuroendocrine tumors in MEN 1A.

Authors:  Mariela Varsavsky; Rebeca Reyes-García; Guillermo Alonso García; Manuel Muñoz-Torres
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.